Gabelli Healthcare & WellnessRx Trust

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM N-Q

QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED

MANAGEMENT INVESTMENT COMPANY

Investment Company Act file number            811-22021       

                         The Gabelli Healthcare & WellnessRx Trust                         

(Exact name of registrant as specified in charter)

One Corporate Center

                             Rye, New York 10580-1422                            

(Address of principal executive offices) (Zip code)

Agnes Mullady

Gabelli Funds, LLC

One Corporate Center

                                 Rye, New York 10580-1422                                

(Name and address of agent for service)

Registrant’s telephone number, including area code:  1-800-422-3554

Date of fiscal year end: December 31

Date of reporting period: September 30, 2018

Form N-Q is to be used by management investment companies, other than small business investment companies registered on Form N-5 (§§ 239.24 and 274.5 of this chapter), to file reports with the Commission, not later than 60 days after the close of the first and third fiscal quarters, pursuant to rule 30b1-5 under the Investment Company Act of 1940 (17 CFR 270.30b1-5). The Commission may use the information provided on Form N-Q in its regulatory, disclosure review, inspection, and policymaking roles.

A registrant is required to disclose the information specified by Form N-Q, and the Commission will make this information public. A registrant is not required to respond to the collection of information contained in Form N-Q unless the Form displays a currently valid Office of Management and Budget (“OMB”) control number. Please direct comments concerning the accuracy of the information collection burden estimate and any suggestions for reducing the burden to the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW, Washington, DC 20549-0609. The OMB has reviewed this collection of information under the clearance requirements of 44 U.S.C. § 3507.


Item 1. Schedule of Investments.

The Schedule(s) of Investments is attached herewith.


The Gabelli Healthcare & WellnessRx Trust

Third Quarter Report — September 30, 2018

(Y)our Portfolio Management Team

 

LOGO   LOGO   LOGO

Mario J. Gabelli, CFA

Chief Investment Officer

 

Kevin V. Dreyer

Co-Chief Investment Officer

BSE, University of Pennsylvania

MBA, Columbia Business School

 

Jeffrey J. Jonas, CFA

Portfolio Manager

BS, Boston College

To Our Shareholders,

For the quarter ended September 30, 2018, the net asset value (NAV) total return of The Gabelli Healthcare & WellnessRx Trust (the Fund) was 10.1%, compared with a total return of 14.5% for the Standard & Poor’s (S&P) 500 Health Care Index. The total return for the Fund’s publicly traded shares was 11.4%. The Fund’s NAV per share was $12.90, while the price of the publicly traded shares closed at $11.03 on the New York Stock Exchange (NYSE). See below for additional performance information.

Enclosed is the schedule of investments as of September 30, 2018.

Comparative Results

Average Annual Returns through September 30, 2018 (a) (Unaudited)

     Quarter   1 Year   3 Year   5 Year   10 Year  

Since
Inception
(06/28/07)

Gabelli Healthcare & WellnessRx Trust

                      

NAV Total Return (b)

       10.05 %       16.94 %       9.64 %       10.38 %       12.62 %   10.34%

Investment Total Return (c)

       11.37       14.76       9.84       9.20       13.53   8.51   

S&P 500 Health Care Index

       14.53       18.35       14.81       15.37       14.22   11.30   

S&P 500 Index

       7.71       17.91       17.31       13.95       11.97   8.33   

S&P 500 Consumer Staples Index

       5.70       2.93       7.56       9.20       10.03   9.38   

50% S&P 500 Health Care Index and 50% S&P 500 Consumer Staples Index (“The Blended Index”)

       10.12       10.64       11.19       12.29       12.13   10.34   
  (a)

Returns represent past performance and do not guarantee future results. Investment returns and the principal value of an investment will fluctuate. The Fund’s use of leverage may magnify the volatility of net asset value changes versus funds that don’t employ leverage. When shares are sold, they may be worth more or less than their original cost. Current performance may be lower or higher than the performance data presented. Visit www.gabelli.com for performance information as of the most recent month end. Performance returns for periods of less than one year are not annualized. Investors should carefully consider the investment objectives, risks, charges, and expenses of the Fund before investing. The S&P 500 Health Care Index is an unmanaged indicator of health care equipment and services, pharmaceuticals, biotechnology, and life sciences stock performance. The S&P 500 Index is an unmanaged indicator of stock market performance. The S&P 500 Consumer Staples Index is an unmanaged indicator of food and staples retailing, food, beverage and tobacco, and household and personal products stock performance. Dividends are considered reinvested. You cannot invest directly in an index.

 
  (b)

Total returns and average annual returns reflect changes in the NAV per share, reinvestment of distributions at NAV on the ex-dividend date, and adjustments for rights offerings and are net of expenses. Since inception return is based on an initial NAV of $8.00.

 
  (c)

Total returns and average annual returns reflect changes in closing market values on the NYSE, reinvestment of distributions, and adjustments for rights offerings. Since inception return is based on an initial offering price of $8.00.

 


The Gabelli Healthcare & WellnessRx Trust

 

Schedule of Investments — September 30, 2018 (Unaudited)

 

 

Shares

        

Market

Value

 
  

COMMON STOCKS — 93.9%

 
  

Beverages — 4.6%

 
  60,000     

China Mengniu Dairy Co. Ltd.

  $ 199,659  
  69,000     

Danone SA

    5,343,496  
  41,000     

ITO EN Ltd.

    1,818,694  
  40,000     

Keurig Dr Pepper Inc.

    926,800  
  29,000     

Massimo Zanetti Beverage Group SpA

    236,366  
  7,000     

Morinaga Milk Industry Co. Ltd.

    190,063  
  300,000     

Parmalat SpA

    989,214  
  20,000     

PepsiCo Inc.

    2,236,000  
  30,000     

Suntory Beverage & Food Ltd.

    1,270,023  
  424,000     

Vitasoy International Holdings Ltd.

    1,446,129  
    

 

 

 
       14,656,444  
    

 

 

 
  

Biotechnology — 5.1%

 
  13,900     

Alexion Pharmaceuticals Inc.†

    1,932,239  
  20,000     

Argenx SE, ADR†

    1,516,800  
  20,000     

Charles River Laboratories International Inc.†

    2,690,800  
  2,000     

Idorsia Ltd.†

    50,377  
  3,800     

Illumina Inc.†

    1,394,828  
  20,000     

Invitae Corp.†

    334,600  
  8,000     

Ligand Pharmaceuticals Inc.†

    2,195,920  
  120,000     

NeoGenomics Inc.†

    1,842,000  
  208,583     

Osiris Therapeutics Inc.†

    2,315,271  
  1,200     

Regeneron Pharmaceuticals Inc.†

    484,848  
  22,000     

Tetraphase Pharmaceuticals Inc.†

    60,720  
  100,000     

Veracyte Inc.†

    955,000  
  1,600     

Waters Corp.†

    311,488  
    

 

 

 
           16,084,891  
    

 

 

 
  

Electronics — 2.3%

 
  30,000     

Thermo Fisher Scientific Inc.

    7,322,400  
    

 

 

 
  

Food — 22.4%

 
  15,000     

Calavo Growers Inc.

    1,449,000  
  35,000     

Campbell Soup Co.

    1,282,050  
  3,200     

Chr. Hansen Holding A/S

    324,838  
  130,000     

Conagra Brands Inc.

    4,416,100  
  30,000     

Dean Foods Co.

    213,000  
  67,500     

Flowers Foods Inc.

    1,259,550  
  67,500     

General Mills Inc.

    2,897,100  
  5,400     

John B Sanfilippo & Son Inc.

    385,452  
  68,500     

Kellogg Co.

    4,796,370  
  35,000     

Kerry Group plc, Cl. A

    3,862,520  
  120,000     

Kikkoman Corp.

    7,139,588  
  38,333     

Lamb Weston Holdings Inc.

    2,552,978  
  66,295     

Lifeway Foods Inc.†

    176,345  
  23,000     

Maple Leaf Foods Inc.

    553,076  
  15,000     

MEIJI Holdings Co. Ltd.

    1,007,305  
  110,000     

Mondelēz International Inc., Cl. A

    4,725,600  
  60,000     

Nestlé SA

    5,002,242  
  80,000     

Pinnacle Foods Inc.

    5,184,800  
  55,000     

Post Holdings Inc.†

    5,392,200  

 

Shares

        

Market

Value

 
  33,000     

The Hain Celestial Group Inc.†

  $ 894,960  
  29,000     

The J.M. Smucker Co.

    2,975,690  
  80,000     

The Kraft Heinz Co.

    4,408,800  
  110,000     

Tingyi (Cayman Islands) Holding Corp.

    202,061  
  75,000     

Unilever plc, ADR

    4,122,750  
  70,000     

Yakult Honsha Co. Ltd.

    5,735,786  
    

 

 

 
       70,960,161  
    

 

 

 
  

Food and Staples Retailing — 4.8%

 
  76,000     

CVS Health Corp.

    5,982,720  
  30,000     

Ingles Markets Inc., Cl. A

    1,027,500  
  45,000     

Sprouts Farmers Market Inc.†

    1,233,450  
  100,000     

The Kroger Co.

    2,911,000  
  83,000     

United Natural Foods Inc.†

    2,485,850  
  20,000     

Walgreens Boots Alliance Inc.

    1,458,000  
    

 

 

 
           15,098,520  
    

 

 

 
  

Health Care Equipment and Supplies — 16.3%

 

  45,000     

Baxter International Inc.

    3,469,050  
  14,500     

Becton, Dickinson and Co.

    3,784,500  
  42,000     

Boston Scientific Corp.†

    1,617,000  
  95,000     

Cardiovascular Systems Inc.†

    3,718,300  
  13,000     

Cutera Inc.†

    423,150  
  40,000     

Gerresheimer AG

    3,378,653  
  20,000     

Globus Medical Inc., Cl. A†

    1,135,200  
  40,000     

Henry Schein Inc.†

    3,401,200  
  400     

ICU Medical Inc.†

    113,100  
  265,000     

InfuSystems Holdings Inc.†

    861,250  
  25,000     

Integer Holdings Corp.†

    2,073,750  
  22,000     

K2M Group Holdings Inc.†

    602,140  
  175,000     

Lantheus Holdings Inc.†

    2,616,250  
  45,000     

Medtronic plc

    4,426,650  
  55,000     

Nevro Corp.†

    3,135,000  
  10,000     

NuVasive Inc.†

    709,800  
  50,000     

Patterson Cos. Inc.

    1,222,500  
  5,000     

Smith & Nephew plc, ADR

    185,450  
  63,782     

Sparton Corp.†

    920,374  
  45,000     

Stericycle Inc.†

    2,640,600  
  15,000     

Stryker Corp.

    2,665,200  
  12,500     

SurModics Inc.†

    933,125  
  8,000     

The Cooper Companies Inc.

    2,217,200  
  39,800     

Zimmer Biomet Holdings Inc.

    5,232,506  
    

 

 

 
       51,481,948  
    

 

 

 
  

Health Care Providers and Services — 18.6%

 

  18,000     

Aetna Inc.

    3,651,300  
  60,000     

AmerisourceBergen Corp.

    5,533,200  
  15,000     

Anthem Inc.

    4,110,750  
  25,000     

athenahealth Inc.†

    3,340,000  
  25,000     

BioTelemetry Inc.†

    1,611,250  
  12,000     

Cigna Corp.

    2,499,000  
  45,000     

DaVita Inc.†

    3,223,350  
  80,000     

Envision Healthcare Corp.†

    3,658,400  
 

 

See accompanying notes to schedule of investments.

 

2


The Gabelli Healthcare & WellnessRx Trust

Schedule of Investments (Continued) — September 30, 2018 (Unaudited)

 

 

Shares

        

Market

Value

 
  

COMMON STOCKS (Continued)

 
  

Health Care Providers and Services (Continued)

 

  170,500     

Evolent Health Inc., Cl. A†

  $ 4,842,200  
  40,000     

Express Scripts Holding Co.†

    3,800,400  
  30,000     

HCA Healthcare Inc.

    4,173,600  
  11,266     

iKang Healthcare Group Inc., ADR†

    203,915  
  60,000     

Kindred Healthcare Inc.†(a)

    540,000  
  22,200     

Laboratory Corp. of America Holdings†

    3,855,696  
  45,000     

LifePoint Health Inc.†

    2,898,000  
  15,000     

McKesson Corp.

    1,989,750  
  47,574     

Orthofix Medical Inc.†

    2,750,253  
  25,000     

PetIQ Inc.†

    982,750  
  1,000     

Teladoc Health Inc.†

    86,350  
  5,000     

Tenet Healthcare Corp.†

    142,300  
  18,900     

UnitedHealth Group Inc.

    5,028,156  
    

 

 

 
           58,920,620  
    

 

 

 
  

Hotels and Gaming — 0.2%

 
  7,500     

Ryman Hospitality Properties Inc., REIT

    646,275  
    

 

 

 
  

Household and Personal Products — 3.8%

 

  25,000     

Avon Products Inc.†

    55,000  
  50,000     

Church & Dwight Co. Inc.

    2,968,500  
  30,000     

Colgate-Palmolive Co.

    2,008,500  
  50,000     

Coty Inc., Cl. A

    628,000  
  35,100     

Edgewell Personal Care Co.†

    1,622,673  
  30,000     

Energizer Holdings Inc.

    1,759,500  
  10,000     

Sally Beauty Holdings Inc.†

    183,900  
  12,000     

The Estee Lauder Companies Inc., Cl. A

    1,743,840  
  13,000     

The Procter & Gamble Co.

    1,081,990  
    

 

 

 
       12,051,903  
    

 

 

 
  

Pharmaceuticals — 14.4%

 
  100,000     

Abbott Laboratories

    7,336,000  
  27,000     

Achaogen Inc.†

    107,730  
  80,000     

Akorn Inc.†

    1,038,400  
  29,600     

Allergan plc

    5,638,208  
  830,000     

BioScrip Inc.†

    2,573,000  
  47,000     

Bristol-Myers Squibb Co.

    2,917,760  
  56,000     

Johnson & Johnson

    7,737,520  
  6,000     

Melinta Therapeutics Inc.†

    23,700  
  80,000     

Merck & Co. Inc.

    5,675,200  
  35,000     

Mylan NV†

    1,281,000  
  68,000     

Pfizer Inc.

    2,996,760  
  12,000     

Roche Holding AG, ADR

    361,920  
  27,500     

Shire plc, ADR

    4,984,925  
  30,000     

Zoetis Inc.

    2,746,800  
    

 

 

 
       45,418,923  
    

 

 

 
  

Specialty Chemicals — 1.4%

 
  31,273     

International Flavors & Fragrances Inc.

    4,350,700  
    

 

 

 
  

TOTAL COMMON STOCKS

    296,992,785  
    

 

 

 

Shares

        

Market

Value

 
  

PREFERRED STOCKS — 0.0%

 
  

Pharmaceuticals — 0.0%

 
  146     

BioScrip Inc., Zero Coupon†

  $ 12,545  
    

 

 

 
  

RIGHTS — 0.0%

 
  

Biotechnology — 0.0%

 
  6,907     

Tobira Therapeutics Inc.†(a)

    414  
    

 

 

 
  

Health Care Equipment and Supplies — 0.0%

 

  40,000     

American Medical Alert Corp., CPR†(a)

    400  
    

 

 

 
  

TOTAL RIGHTS

    814  
    

 

 

 
  

WARRANTS — 0.0%

 
  

Pharmaceuticals — 0.0%

 
  420     

BioScrip Inc., Cl. A, expire 07/27/25†

    87  
  420     

BioScrip Inc., Cl. B, expire 07/27/25†

    60  
    

 

 

 
       147  
    

 

 

 
  

TOTAL WARRANTS

    147  
    

 

 

 

Principal

Amount

            
  

U.S. GOVERNMENT OBLIGATIONS — 6.1%

 

  $19,232,000     

U.S. Treasury Bills,
2.002% to 2.204%††,
11/08/18 to 02/07/19

    19,145,947  
    

 

 

 
  

TOTAL INVESTMENTS — 100.0%
(Cost $220,767,599)

  $ 316,152,238  
    

 

 

 

 

(a)

Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.

Non-income producing security.

††

Represents annualized yields at dates of purchase.

ADR

American Depository Receipt

CPR

Contingent Payment Right

REIT

Real Estate Investment Trust

 

 

See accompanying notes to schedule of investments.

 

3


The Gabelli Healthcare & WellnessRx Trust

Schedule of Investments (Continued) — September 30, 2018 (Unaudited)

 

 

Geographic Diversification

 

% of Total
Investments

 

Market

Value

North America

      84.5 %     $ 267,082,740

Europe

      9.4       29,856,276

Japan

      5.4       17,161,459

Asia/Pacific

      0.7       2,051,763
   

 

 

     

 

 

 

Total Investments

      100.0 %     $ 316,152,238
   

 

 

     

 

 

 
 

 

See accompanying notes to schedule of investments.

 

4


The Gabelli Healthcare and WellnessRx Fund

Notes to Schedule of Investments (Unaudited)

 

As an investment company, the Fund follows the investment company accounting and reporting guidance, which is part of U.S. generally accepted accounting principles (GAAP) that may require the use of management estimates and assumptions in the preparation of its schedule of investments. Actual results could differ from those estimates. The following is a summary of significant accounting policies followed by the Fund in the preparation of its schedule of investments.

Security Valuation. Portfolio securities listed or traded on a nationally recognized securities exchange or traded in the U.S. over-the-counter market for which market quotations are readily available are valued at the last quoted sale price or a market’s official closing price as of the close of business on the day the securities are being valued. If there were no sales that day, the security is valued at the average of the closing bid and asked prices or, if there were no asked prices quoted on that day, then the security is valued at the closing bid price on that day. If no bid or asked prices are quoted on such day, the security is valued at the most recently available price or, if the Board of Trustees (the Board) so determines, by such other method as the Board shall determine in good faith to reflect its fair market value. Portfolio securities traded on more than one national securities exchange or market are valued according to the broadest and most representative market, as determined by Gabelli Funds, LLC (the Adviser).

Portfolio securities primarily traded on a foreign market are generally valued at the preceding closing values of such securities on the relevant market, but may be fair valued pursuant to procedures established by the Board if market conditions change significantly after the close of the foreign market, but prior to the close of business on the day the securities are being valued. Debt obligations for which market quotations are readily available are valued at the average of the latest bid and asked prices. If there were no asked prices quoted on such day, the security is valued using the closing bid price, unless the Board determines such amount does not reflect the securities’ fair value, in which case these securities will be fair valued as determined by the Board. Certain securities are valued principally using dealer quotations. Futures contracts are valued at the closing settlement price of the exchange or board of trade on which the applicable contract is traded. OTC futures and options on futures for which market quotations are readily available will be valued by quotations received from a pricing service or, if no quotations are available from a pricing service, by quotations obtained from one or more dealers in the instrument in question by the Adviser.

Securities and assets for which market quotations are not readily available are fair valued as determined by the Board. Fair valuation methodologies and procedures may include, but are not limited to: analysis and review of available financial and non-financial information about the company; comparisons with the valuation and changes in valuation of similar securities, including a comparison of foreign securities with the equivalent U.S. dollar value American Depositary Receipt securities at the close of the U.S. exchange; and evaluation of any other information that could be indicative of the value of the security.

The inputs and valuation techniques used to measure fair value of the Fund’s investments are summarized into three levels as described in the hierarchy below:

   

Level 1 — quoted prices in active markets for identical securities;

   

Level 2 — other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.); and

   

Level 3 — significant unobservable inputs (including the Board’s determinations as to the fair value of investments).

 

5


The Gabelli Healthcare and WellnessRx Fund

Notes to Schedule of Investments (Unaudited) (Continued)

 

 

A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input both individually and in the aggregate that is significant to the fair value measurement. The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities. The summary of the Fund’s investments in securities by inputs used to value the Fund’s investments as of September 30, 2018 is as follows:

 

     Valuation Inputs         
     Level 1
Quoted Prices
     Level 2 Other Significant
Observable Inputs
     Level 3 Significant
Unobservable Inputs
     Total Market Value
at 9/30/18
 

INVESTMENTS IN SECURITIES:

           

ASSETS (Market Value):

           

Common Stocks (a)

     $296,452,785        —                    $540,000                    $296,992,785    

Preferred Stocks (a)

            $       12,545                    —                    12,545    

Rights (a)

            —                    814                    814    

Warrants (a)

            147                    —                    147    

U.S. Government Obligations

            19,145,947                    —                    19,145,947    

 

 

TOTAL INVESTMENTS IN SECURITIES – ASSETS

     $296,452,785        $19,158,639                    $540,814                    $316,152,238    

 

 

 

(a)

Please refer to the Schedule of Investments for the industry classifications of these portfolio holdings.

Additional Information to Evaluate Qualitative Information.

General. The Fund uses recognized industry pricing services – approved by the Board and unaffiliated with the Adviser – to value most of its securities, and uses broker quotes provided by market makers of securities not valued by these and other recognized pricing sources. Several different pricing feeds are received to value domestic equity securities, international equity securities, preferred equity securities, and fixed income securities. The data within these feeds are ultimately sourced from major stock exchanges and trading systems where these securities trade. The prices supplied by external sources are checked by obtaining quotations or actual transaction prices from market participants. If a price obtained from the pricing source is deemed unreliable, prices will be sought from another pricing service or from a broker/dealer that trades that security or similar securities.

Fair Valuation. Fair valued securities may be common or preferred equities, warrants, options, rights, or fixed income obligations. Where appropriate, Level 3 securities are those for which market quotations are not available, such as securities not traded for several days, or for which current bids are not available, or which are restricted as to transfer. When fair valuing a security, factors to consider include recent prices of comparable securities that are publicly traded, reliable prices of securities not publicly traded, the use of valuation models, current analyst reports, valuing the income or cash flow of the issuer, or cost if the preceding factors do not apply. A significant change in the unobservable inputs could result in a lower or higher value in Level 3 securities. The circumstances of Level 3 securities are frequently monitored to determine if fair valuation measures continue to apply.

The Adviser reports quarterly to the Board the results of the application of fair valuation policies and procedures. These may include backtesting the prices realized in subsequent trades of these fair valued securities to fair values previously recognized.

 

6


The Gabelli Healthcare and WellnessRx Fund

Notes to Schedule of Investments (Unaudited) (Continued)

 

 

Foreign Currency Translations. The books and records of the Fund are maintained in U.S. dollars. Foreign currencies, investments, and other assets and liabilities are translated into U.S. dollars at current exchange rates. Purchases and sales of investment securities, income, and expenses are translated at the exchange rate prevailing on the respective dates of such transactions. Unrealized gains and losses that result from changes in foreign exchange rates and/or changes in market prices of securities have been included in unrealized appreciation/depreciation on investments and foreign currency translations. Net realized foreign currency gains and losses resulting from changes in exchange rates include foreign currency gains and losses between trade date and settlement date on investment securities transactions, foreign currency transactions, and the difference between the amounts of interest and dividends recorded on the books of the Fund and the amounts actually received. The portion of foreign currency gains and losses related to fluctuation in exchange rates between the initial purchase trade date and subsequent sale trade date is included in realized gain/(loss) on investments.

Foreign Securities. The Fund may directly purchase securities of foreign issuers. Investing in securities of foreign issuers involves special risks not typically associated with investing in securities of U.S. issuers. The risks include possible revaluation of currencies, the inability to repatriate funds, less complete financial information about companies, and possible future adverse political and economic developments. Moreover, securities of many foreign issuers and their markets may be less liquid and their prices more volatile than securities of comparable U.S. issuers.

Foreign Taxes. The Fund may be subject to foreign taxes on income, gains on investments, or currency repatriation, a portion of which may be recoverable. The Fund will accrue such taxes and recoveries as applicable, based upon its current interpretation of tax rules and regulations that exist in the markets in which it invests.

Tax Information. The Fund intends to continue to qualify as a regulated investment company under Subchapter M of the Internal Revenue Code of 1986, as amended.

 

7


THE GABELLI HEALTHCARE & WELLNESSRx TRUST

One Corporate Center

Rye, NY 10580-1422

Portfolio Management Team Biographies

Mario J. Gabelli, CFA, is Chairman, Chief Executive Officer, and Chief Investment Officer - Value Portfolios of GAMCO Investors, Inc. that he founded in 1977, and Chief Investment Officer - Value Portfolios of Gabelli Funds, LLC and GAMCO Asset Management Inc. He is also Executive Chairman of Associated Capital Group, Inc. Mr. Gabelli is a summa cum laude graduate of Fordham University and holds an MBA degree from Columbia Business School and Honorary Doctorates from Fordham University and Roger Williams University.

Kevin V. Dreyer joined Gabelli in 2005 as a research analyst covering companies within the consumer sector. Currently he is a Managing Director and Co-Chief Investment Officer for GAMCO Investors, Inc.’s Value team. In addition, he serves as a portfolio manager of Gabelli Funds, LLC and manages several funds within the Gabelli/GAMCO Fund Complex. Mr. Dreyer received a BSE from the University of Pennsylvania and an MBA degree from Columbia Business School.

Jeffrey J. Jonas, CFA, joined Gabelli in 2003 as a research analyst focusing on companies across the healthcare industry. In 2006, he began serving as a portfolio manager of Gabelli Funds, LLC and manages several funds within the Gabelli/GAMCO Fund Complex. Mr. Jonas was a Presidential Scholar at Boston College, where he received a BS in Finance and Management Information Systems.

 

We have separated the portfolio managers’ commentary from the financial statements and investment portfolio due to corporate governance regulations stipulated by the Sarbanes-Oxley Act of 2002. We have done this to ensure that the content of the portfolio managers’ commentary is unrestricted. Both the commentary and the financial statements, including the portfolio of investments, will be available on our website at www.gabelli.com.

The Net Asset Value per share appears in the Publicly Traded Funds column, under the heading “Specialized Equity Funds,” in Monday’s The Wall Street Journal. It is also listed in Barron’s Mutual Funds/Closed End Funds section under the heading “Specialized Equity Funds.”

The Net Asset Value per share may be obtained each day by calling (914) 921-5070 or visiting www.gabelli.com.

The NASDAQ symbol for the Net Asset Value is “XXGRX.”

 

Notice is hereby given in accordance with Section 23(c) of the Investment Company Act of 1940, as amended, that the Fund may from time to time purchase its common shares in the open market when the Fund’s shares are trading at a discount of 10% or more from the net asset value of the shares. The Fund may also, from time to time, purchase its preferred shares in the open market when the preferred shares are trading at a discount to the liquidation value.


THE GABELLI HEALTHCARE & WELLNESSRX TRUST

One Corporate Center

Rye, NY 10580-1422

 

t

800-GABELLI (800-422-3554)

 

f

914-921-5118

 

e

info@gabelli.com

  GABELLI.COM

 

 

 

TRUSTEES

Mario J. Gabelli, CFA

Chairman &

Chief Executive Officer,

GAMCO Investors, Inc.

Executive Chairman,

Associated Capital Group, Inc.

Anthony J. Colavita

President,

Anthony J. Colavita, P.C.

James P. Conn

Former Managing Director &

Chief Investment Officer,

Financial Security Assurance

Holdings Ltd.

Vincent D. Enright

Former Senior Vice President &

Chief Financial Officer,

KeySpan Corp.

Jeffrey J. Jonas, CFA

Portfolio Manager,

Gabelli Funds, LLC

Robert C. Kolodny

Physician,

Principal of KBS

Management LLC

Kuni Nakamura

President,

Advanced Polymer, Inc.

Anthonie C. van Ekris

Chairman,

BALMAC International, Inc.

Salvatore J. Zizza

Chairman,

Zizza & Associates Corp.

OFFICERS

Agnes Mullady

President

John C. Ball

Treasurer

Andrea R. Mango

Secretary & Vice President

Richard J. Walz

Chief Compliance Officer

Bethany A. Uhlein

Vice President & Ombudsman

David I. Schachter

Vice President

Adam E. Tokar

Vice President

INVESTMENT ADVISER

Gabelli Funds, LLC

One Corporate Center

Rye, New York 10580-1422

CUSTODIAN

The Bank of New York Mellon

COUNSEL

Willkie Farr & Gallagher LLP

TRANSFER AGENT AND REGISTRAR

Computershare Trust Company, N.A.

 

 

 

 

GRX Q3/2018

LOGO

 


Item 2. Controls and Procedures.

 

 

(a)

The registrant’s principal executive and principal financial officers, or persons performing similar functions, have concluded that the registrant’s disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940, as amended (the “1940 Act”) (17 CFR 270.30a-3(c))) are effective, as of a date within 90 days of the filing date of the report that includes the disclosure required by this paragraph, based on their evaluation of these controls and procedures required by Rule 30a-3(b) under the 1940 Act (17 CFR 270.30a-3(b)) and Rules 13a-15(b) or 15d-15(b) under the Securities Exchange Act of 1934, as amended (17 CFR 240.13a-15(b) or 240.15d-15(b)).

 

 

(b)

There were no changes in the registrant’s internal control over financial reporting (as defined in Rule 30a-3(d) under the 1940 Act (17 CFR 270.30a-3(d))) that occurred during the registrant’s last fiscal quarter that have materially affected, or are reasonably likely to materially affect, the registrant’s internal control over financial reporting.

Item 3. Exhibits.

Certifications pursuant to Rule 30a-2(a) under the 1940 Act and Section 302 of the Sarbanes-Oxley Act of 2002 are attached hereto.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

(Registrant)

  

  The Gabelli Healthcare & WellnessRx Trust

 

By (Signature and Title)*

  

  /s/ Agnes Mullady

  

  Agnes Mullady, Principal Executive Officer

 

Date

  

  11/16/2018

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

By (Signature and Title)*

  

  /s/ Agnes Mullady

  

  Agnes Mullady, Principal Executive Officer

 

Date

  

  11/16/2018

 

By (Signature and Title)*

  

  /s/ John C. Ball

  

  John C. Ball, Principal Financial Officer

 

Date

  

  11/16/2018

* Print the name and title of each signing officer under his or her signature.